Term
| when do acute exacerbations not need to be treated? |
|
Definition
| when dont result in function decline |
|
|
Term
| if treating for acut excaerbation what d you give |
|
Definition
| methylprednisolone 500 mg IV x 3 days |
|
|
Term
| what is the benefit of giving steroid with acute exacerbatin-3 |
|
Definition
shorten length of exacerb
delay tiem til next occurance
reduce edema |
|
|
Term
| what are first line theapies for disease modifying-3 |
|
Definition
| interferon B1b and interferon B1a and glatiramer acetate |
|
|
Term
|
Definition
reduce annual replase rates and MRI burden
slow brain atrophy and cogntivie decline |
|
|
Term
|
Definition
reduce interferon secrection by lymphocytes
suppress T cell and BBB permeability
increase CD56 antural killer cells and Treg cells |
|
|
Term
|
Definition
elevated LFTs
decrease CBC
injection site
depression
thyroid |
|
|
Term
| monitoring for interferons-3 |
|
Definition
CBC 1 mo,q 3 mo, then q6
LEFTs same as above
neutralizing antibody testing |
|
|
Term
|
Definition
|
|
Term
|
Definition
| 25 mcg SQ every toher day |
|
|
Term
|
Definition
|
|
Term
|
Definition
| 22 or 44 mcg SQ three times weekly |
|
|
Term
| what is the pearl about IFN B1a meds |
|
Definition
| refridge, but can be at room temp for 30 days |
|
|
Term
|
Definition
|
|
Term
|
Definition
| reduce relapse rate by 30% and releive MRI burdern |
|
|
Term
| which drug may slow progression of relapse/remitting MS? |
|
Definition
|
|
Term
| which drug cna you use safely for 10 yrs |
|
Definition
|
|
Term
|
Definition
polypet of L alaline, glut, lysine, tyroinse
mimics myelin basic protein (MBP)
induce T suppressor cell for mylin
induce BDNF for neuroprotection |
|
|
Term
|
Definition
injection site
one time chest tightening/flushing |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
reduce CNS lesion by 90%
decrease relapse by 60%
slow progression of disability |
|
|
Term
|
Definition
humanized mono antibody
attached very late antigen to block VCAM-1 and decrease lympohcyte entry thru BB |
|
|
Term
|
Definition
injection site
devleop neutralizing antibodies
rare PML |
|
|
Term
| monitoring for natiluzamb |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| which drug decreases relapse by 50% |
|
Definition
|
|
Term
|
Definition
sphingosine 1 phos recpt agonist
requesters lymphocytes into 2nd lymph organs |
|
|
Term
|
Definition
LEFTs
lymphopenia
macular edema
ifx |
|
|
Term
| monitoring for fingolimod-3 |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
which drug is last line agent
why? |
|
Definition
mitoxantrone
cardiac toxnad leukemia |
|
|
Term
| mitoxantrone is FDA approvedd for-3 |
|
Definition
| neuro disability in secondary porgressive MS, primary progressive, or woresning relapse |
|
|
Term
| mitoxantone is 15 min IV infusion q 3 months* |
|
Definition
|
|
Term
| montioring for mitoxantrone-2 |
|
Definition
| ECG and LVF befoer ea/ infusion |
|
|
Term
|
Definition
| UTI, resp infx, alopecia, menstrual |
|
|
Term
| which med doesnt ahve FDA approval |
|
Definition
|
|
Term
|
Definition
baclofen
tizandine
gabapentin |
|
|
Term
|
Definition
antimuscarinic- oxybutyin, trospium
prazosin |
|
|
Term
|
Definition
|
|
Term
tx for depression
which agents do you watch fro this closely in? |
|
Definition
antidepressents
interferons and natiluzumab |
|
|
Term
|
Definition
|
|
Term
| tx for sex dysfunction (only for men)-3 |
|
Definition
| taldalifil sildenifil, vardenifil |
|
|
Term
|
Definition
modafinil
amantafine
amphetamines |
|
|
Term
| tx for impaired cognition-2 |
|
Definition
stimulants
cholintesterase inhbitiors |
|
|
